Analysts Set Medpace Holdings, Inc. (NASDAQ:MEDP) Target Price at $486.67
by Teresa Graham · The Cerbat GemShares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) have received an average rating of “Hold” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $486.6667.
A number of research firms recently issued reports on MEDP. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research note on Friday, February 13th. Truist Financial decreased their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada assumed coverage on Medpace in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 target price on the stock.
Check Out Our Latest Stock Report on Medpace
Key Headlines Impacting Medpace
Here are the key news stories impacting Medpace this week:
- Positive Sentiment: Medpace reported a strong quarterly result (beat on EPS and revenue) and set FY2026 EPS guidance, which remains a supportive fundamental anchor for the stock despite the legal headlines.
- Neutral Sentiment: An analyst comparison piece discusses valuation alternatives between Medpace and PACS Group, which may interest value investors but does not directly change near‑term litigation risk. PACS vs. MEDP: Which Stock Is the Better Value Option?
- Negative Sentiment: Multiple law firms (including Howard G. Smith, Frank R. Cruz, Rosen, Pomerantz, Wolf Haldenstein, Robbins, Faruqi & Faruqi and others) have announced securities‑fraud investigations or class‑action filings alleging misstatements/omissions tied to disclosures spanning Apr 22, 2025–Feb 9, 2026; several firms are soliciting lead‑plaintiff motions with June deadlines — a broad flurry that increases potential legal costs, management distraction, and investor uncertainty. Howard G. Smith notice
- Negative Sentiment: An investor lawsuit reported by Bloomberg Law alleges misleading demand projections and links those claims to a prior ~16% stock drop—this is a specific, potentially material claim that amplifies the litigation narrative and could influence future settlements or disclosures. Medpace investor sues over demand projections
- Negative Sentiment: Additional firm notices (e.g., Pomerantz, Rosen, Faruqi) remind investors of upcoming deadlines to join suits or seek lead‑plaintiff status; accumulation of these notices keeps the litigation story front‑and‑center for investors. Pomerantz investor alert
Medpace Stock Performance
NASDAQ:MEDP opened at $501.50 on Tuesday. Medpace has a 52-week low of $250.05 and a 52-week high of $628.92. The firm has a market cap of $14.32 billion, a price-to-earnings ratio of 32.78, a PEG ratio of 2.50 and a beta of 1.39. The business’s fifty day moving average is $474.67 and its 200 day moving average is $537.17.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period in the previous year, the company posted $3.67 EPS. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts predict that Medpace will post 12.29 EPS for the current fiscal year.
Insiders Place Their Bets
In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.30% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Medpace
A number of institutional investors have recently added to or reduced their stakes in MEDP. Quent Capital LLC bought a new position in Medpace in the 3rd quarter worth about $25,000. Optiver Holding B.V. bought a new position in Medpace in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace during the 4th quarter valued at about $30,000. Finally, Elyxium Wealth LLC bought a new position in shares of Medpace during the 4th quarter valued at about $30,000. 77.98% of the stock is currently owned by institutional investors.
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.